

Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-Apr-2024
Document Type: USP Monographs
DocId: GUID-8F30FDAB-0124-4FE1-879F-E2272DDA00AE_5_en-US
DOI: https://doi.org/10.31003/USPNF_M39490_05_01
DOI Ref: se5nl

© 2025 USPC
Do not distribute

Hydroxyzine Hydrochloride Tablets

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click www.uspnf.com/rb-hydroxyzine-hcl-tabs-20240329.

DEFINITION

Hydroxyzine Hydrochloride Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of hydroxyzine hydrochloride ($C_{21}H_{27}ClN_2O_2 \cdot 2HCl$).

IDENTIFICATION

- A.** The retention time of the main peak of the *Sample solution* corresponds to that of the hydroxyzine peak of the *Standard solution*, as obtained in the Assay.
- B.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• **PROCEDURE**

- Solution A:** [Trifluoroacetic acid](#) and [water](#) (0.1: 99.9)
Solution B: [Trifluoroacetic acid](#) and [acetonitrile](#) (0.05: 99.95)
Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	90	10
4	90	10
12	55	45
16	55	45
21	20	80
25	20	80
26	90	10
30	90	10

- Diluent:** [Acetonitrile](#) and [water](#) (30:70)
Standard solution: 0.05 mg/mL of [USP Hydroxyzine Hydrochloride RS](#) in *Diluent*
Sample stock solution: Nominally 0.5 mg/mL of hydroxyzine hydrochloride from Tablets in *Diluent* prepared as follows. Transfer a portion of finely powdered Tablets (NLT 10), equivalent to 50 mg of hydroxyzine hydrochloride, to a 100-mL volumetric flask and add 80 mL of *Diluent*. Sonicate for 30 min to dissolve and dilute with *Diluent* to volume. Centrifuge the solution and use the supernatant. [NOTE—The use of a centrifuge speed of 3000 rpm for 10 min may be suitable.]
Sample solution: Nominally 0.05 mg/mL of hydroxyzine hydrochloride from the *Sample stock solution* in *Diluent*
Chromatographic system
(See [Chromatography \(621\), System Suitability](#).)
Mode: LC
Detector: UV 230 nm. For *Identification B*, use a diode array detector in the range of 200–400 nm.
Column: 2.1-mm × 15-cm; 1.8-μm packing [L1](#)
Flow rate: 0.3 mL/min
Injection volume: 2 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 1.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of hydroxyzine hydrochloride ($C_{21}H_{27}ClN_2O_2 \cdot 2HCl$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Hydroxyzine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of hydroxyzine hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

Change to read:

- [DISSOLUTION \(711\)](#).

Test 1

Medium: [Water](#); 900 mL

Apparatus 2: 50 rpm

Time: 45 min

Standard solution: [USP Hydroxyzine Hydrochloride RS](#) in *Medium*

Sample solution: Use a filtered portion of the solution under test. Dilute with *Medium*, if necessary.

Instrumental conditions

Mode: UV

Analytical wavelength: Maximum absorbance at about 230 nm

Analysis

Samples: *Standard solution* and *Sample solution*

Determine the percentage of the labeled amount of hydroxyzine hydrochloride ($C_{21}H_{27}ClN_2O_2 \cdot 2HCl$) dissolved from the UV absorbances.

Tolerances: NLT 75% (Q) of the labeled amount of hydroxyzine hydrochloride ($C_{21}H_{27}ClN_2O_2 \cdot 2HCl$) is dissolved.

Test 2: If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.

Medium: [Water](#); 250 mL

Apparatus 3: 30 dips/min

Time: 45 min

Standard solution: [USP Hydroxyzine Hydrochloride RS](#) in *Medium*

Sample solution: Use a filtered portion of the solution under test. Dilute with *Medium*, if necessary.

Instrumental conditions

Mode: UV

Analytical wavelength: Maximum absorbance at about 230 nm

Analysis

Samples: *Standard solution* and *Sample solution*

Determine the percentage of the labeled amount of hydroxyzine hydrochloride ($C_{21}H_{27}ClN_2O_2 \cdot 2HCl$) dissolved from the UV absorbances.

Tolerances: NLT 75% (Q) of the labeled amount of hydroxyzine hydrochloride ($C_{21}H_{27}ClN_2O_2 \cdot 2HCl$) is dissolved.

▲ **Test 3:** If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 3*.

Medium: 0.1 N [hydrochloric acid](#); 500 mL

Apparatus 2: 50 rpm

Time: 30 min

Buffer: Dissolve 1.38 g of [potassium phosphate, monobasic](#) in 1 L of [water](#). Adjust with [phosphoric acid](#) to a pH of 2.5.

Mobile phase: [Acetonitrile](#) and *Buffer* (40:60)

Standard solution: 0.02 mg/mL of [USP Hydroxyzine Hydrochloride RS](#) in *Medium*. Sonicate to dissolve, if necessary.

Sample solution: Pass a portion of the solution under test through a suitable filter of 10-μm pore size. Dilute with *Medium* to a concentration similar to that of the *Standard solution*, if necessary. Pass through a suitable filter of 0.45-μm pore size, discarding an appropriate volume of filtrate so that a consistent result can be obtained.

Chromatographic system

(See [Chromatography \(621\), System Suitability.](#))

Mode: LC

Detector: UV 230 nm

Column: 4.6-mm × 15-cm; 5-μm packing [L1](#)

Column temperature: 45°

Flow rate: 1 mL/min

Injection volume: 10 μL

Run time: NLT 2.7 times the retention time of hydroxyzine

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 2.0

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Determine the percentage of the labeled amount of hydroxyzine hydrochloride ($C_{21}H_{27}ClN_2O_2 \cdot 2HCl$) dissolved.

$$\text{Result} = (r_U/r_S) \times C_S \times V \times D \times (1/L) \times 100$$

r_U = peak response of hydroxyzine from the *Sample solution*

r_S = peak response of hydroxyzine from the *Standard solution*

C_S = concentration of [USP Hydroxyzine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

V = volume of the *Medium*, 500 mL

D = dilution factor of the *Sample solution*, if necessary

L = label claim (mg/tablet)

Tolerances: NLT 80% (Q) of the labeled amount of hydroxyzine hydrochloride ($C_{21}H_{27}ClN_2O_2 \cdot 2HCl$) is dissolved ▲ (RB 1-Apr-2024)

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): Meet the requirements

IMPURITIES

• ORGANIC IMPURITIES

Solution A, Solution B, Mobile phase, and Diluent: Proceed as directed in the Assay.

Standard stock solution: 25.0 μg/mL each of [USP Hydroxyzine Hydrochloride RS](#), [USP Hydroxyzine Related Compound A RS](#), and [USP 4-Chlorobenzophenone RS](#) in *Diluent*

Standard solution: 1.0 μg/mL each of [USP Hydroxyzine Hydrochloride RS](#), [USP Hydroxyzine Related Compound A RS](#), and [USP 4-Chlorobenzophenone RS](#) from the *Standard stock solution* in *Diluent*

Sample solution: Nominally 500 μg/mL of hydroxyzine hydrochloride from Tablets prepared as follows. Transfer a portion of finely powdered Tablets (NLT 10), equivalent to 50 mg of hydroxyzine hydrochloride, to a 100-mL volumetric flask. Add 80 mL of *Diluent*. Sonicate 30 min to dissolve and dilute with *Diluent* to volume. Centrifuge the solution and use the supernatant. [NOTE—The use of a centrifuge speed of 3000 rpm for 10 min may be suitable.]

Chromatographic system

(See [Chromatography \(621\), System Suitability.](#))

Mode: LC

Detectors

Hydroxyzine and hydroxyzine related compound A: UV 230 nm

4-Chlorobenzophenone: UV 254 nm

Column: 2.1-mm × 15-cm; 1.8-μm packing [L1](#)

Flow rate: 0.3 mL/min

Injection volume: 2 μL

System suitability

Sample: *Standard solution*

[NOTE—See [Table 2](#) for the relative retention times.]

Suitability requirements

Resolution: NLT 5.0 between hydroxyzine related compound A and hydroxyzine

Relative standard deviation: NMT 3.0% each for hydroxyzine related compound A, hydroxyzine, and 4-chlorobenzophenone

Analysis

Samples: *Standard solution* and *Sample solution*

For degradation products detected at UV 230 nm

Calculate the percentage of any individual unspecified degradation product in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of each unspecified degradation product from the *Sample solution*

r_S = peak response of hydroxyzine from the *Standard solution*

C_S = concentration of [USP Hydroxyzine Hydrochloride RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of hydroxyzine hydrochloride in the *Sample solution* (µg/mL)

For 4-chlorobenzophenone detected at UV 254 nm

Calculate the percentage of 4-chlorobenzophenone in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of 4-chlorobenzophenone from the *Sample solution*

r_S = peak response of 4-chlorobenzophenone from the *Standard solution*

C_S = concentration of [USP 4-Chlorobenzophenone RS](#) in the *Standard solution* (µg/mL)

C_U = nominal concentration of hydroxyzine hydrochloride in the *Sample solution* (µg/mL)

Acceptance criteria: See [Table 2](#). Disregard any peak below 0.03%.

Table 2

Name	Relative Retention Time	Acceptance Criteria, NMT (%)
Decloxizine ^a	0.87	—
Hydroxyzine related compound A ^a	0.96	—
Hydroxyzine	1.0	—
4-Chlorobenzophenone	1.4	0.2
Any individual unspecified degradation product	—	0.3
Total degradation products	—	0.5

^a These are process impurities that are controlled in the drug substance. They are not to be reported or included in the total degradation products.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers. Store at controlled room temperature.
- **LABELING:** When more than one *Dissolution* test is given, the labeling states the *Dissolution* test used only if *Test 1* is not used.
- **USP REFERENCE STANDARDS (11).**

[USP 4-Chlorobenzophenone RS](#)

4-Chlorobenzophenone.

C₁₃H₉ClO 216.66

[USP Hydroxyzine Hydrochloride RS](#)

[USP Hydroxyzine Related Compound A RS](#)

1-[(4-Chlorophenyl)phenylmethyl]piperazine;

Also known as *p*-Chlorobenzhydrylpiperazine.

C₁₇H₁₉ClN₂ 286.80

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
HYDROXYZINE HYDROCHLORIDE TABLETS	Documentary Standards Support	SM42020 Small Molecules 4

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 41(1)

Current DocID: GUID-8F30FDAB-0124-4FE1-879F-E2272DDA00AE_5_en-US

DOI: https://doi.org/10.31003/USPNF_M39490_05_01

DOI ref: [se5nl](#)

OFFICIAL